Compare OMH & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OMH | RNTX |
|---|---|---|
| Founded | 2015 | 2001 |
| Country | Singapore | United States |
| Employees | N/A | 11 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.7M | 30.0M |
| IPO Year | 2022 | N/A |
| Metric | OMH | RNTX |
|---|---|---|
| Price | $1.25 | $1.25 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 23.9K | ★ 98.8K |
| Earning Date | 11-28-2025 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $28.40 | N/A |
| Revenue Next Year | $23.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.59 | $1.02 |
| 52 Week High | $4.33 | $2.22 |
| Indicator | OMH | RNTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.78 | 44.91 |
| Support Level | $1.03 | $1.07 |
| Resistance Level | $1.37 | $1.30 |
| Average True Range (ATR) | 0.09 | 0.13 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 60.98 | 20.00 |
Ohmyhome Ltd is a data and technology-driven property technology company based in Singapore. Through its subsidiaries, it operates a one-stop-shop property platform that provides end-to-end property solutions and services for its customers, which comprises brokerage services and emerging and other services, such as home renovation and furnishing services, listing and research, mortgage referral, legal services, and insurance referral services. The company derives its revenues from two sources: revenue from brokerage services, property management services, and revenue from emerging and other services.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.